Ownership and insider activity for None (QURE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease.
Price
| Price | $42.49 |
| Market Cap | $2.9B |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | M-Exempt | 21,082 | $409K |
| 2026-07-02 | Kapusta Matthew C | S-Sale | 9,200 | $409K |
| 2026-07-02 | Kapusta Matthew C | S-Sale | 4,282 | $195K |
| 2026-07-02 | Kapusta Matthew C | S-Sale | 7,600 | $349K |
| 2026-07-02 | Kapusta Matthew C | M-Exempt | 21,082 | $409K |
| 2026-06-30 | Abi-Saab Walid | M-Exempt | 10,000 | $56K |
| 2026-06-30 | Abi-Saab Walid | S-Sale | 10,000 | $465K |
| 2026-06-30 | Abi-Saab Walid | S-Sale | 20,000 | $928K |
| 2026-06-30 | Abi-Saab Walid | M-Exempt | 10,000 | $56K |
| 2026-06-30 | Kaye Jack | M-Exempt | 17,060 | $344K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $132.5M | $159.4M | $234.9M | $377.8M | $244.9M | $556.3M | $228.0M | $241.4M | $158.9M | $80.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $124.8M | $376.5M | $208.6M | $542.3M |
| Receivables | $9.2M | $1.6M | $233000 | $947000 | $6.6M | $58.8M | $102.4M | $4.2M | $5.9M | $5.9M |
| Inventory | $996000 | $1.1M | $1.1M | 0 | 0 | 0 | $6.9M | $12.0M | 0 | 0 |
| Total Current Assets | $143.9M | $162.8M | $236.6M | $384.2M | $258.9M | $628.2M | $476.8M | $651.9M | $390.3M | $656.0M |
| Property, Plant & Equipment | $35.7M | $34.3M | $29.2M | $55.6M | $58.4M | $69.1M | $83.3M | $75.3M | $34.1M | $26.3M |
| Goodwill | $465000 | $530000 | $506000 | $496000 | $542000 | $27.6M | $25.6M | $26.4M | $22.4M | $25.4M |
| Intangible Assets | $8.3M | $8.8M | $5.2M | $5.4M | $3.4M | $62.7M | $58.8M | $60.5M | $71.0M | $72.8M |
| Total Assets | $190.3M | $208.9M | $273.9M | $448.6M | $340.4M | $809.2M | $705.0M | $831.7M | $556.5M | $824.9M |
| Accounts Payable | $5.5M | $2.9M | $3.8M | $5.7M | $3.8M | $2.5M | $11.0M | $6.6M | $7.2M | $5.2M |
| Short-term Debt | $605000 | $1.1M | 0 | 0 | $5.5M | $5.8M | $8.4M | 0 | 0 | $3.9M |
| Total Current Liabilities | $22.7M | $19.3M | $20.0M | $31.6M | $27.3M | $36.8M | $75.9M | $73.7M | $40.1M | $62.9M |
| Long-term Debt | $19.6M | $19.7M | $35.5M | $36.1M | $35.6M | $101.0M | $102.8M | $101.7M | $51.3M | $522.9M |
| Total Liabilities | $126.6M | $118.9M | $94.3M | $125.6M | $96.5M | $213.4M | $229.0M | $624.0M | $563.3M | $626.0M |
| Retained Earnings | -$396.1M | -$467.1M | -$535.5M | -$659.7M | -$784.7M | -$455.1M | -$581.9M | -$890.4M | -$1.13B | -$1.33B |
| Total Equity | $63.6M | $89.9M | $179.6M | $323.1M | $243.9M | $595.8M | $476.0M | $207.7M | -$6.8M | $198.9M |
| Total Debt | $20.2M | $20.2M | $35.5M | $73.1M | $71.5M | $135.7M | $142.9M | $138.4M | $66.1M | $536.6M |
| Net Debt | -$112.3M | -$139.2M | -$199.4M | -$304.7M | -$173.4M | -$420.5M | -$210.0M | -$479.5M | -$301.5M | -$85.9M |
| Working Capital | $121.2M | $143.5M | $216.6M | $352.6M | $231.6M | $591.5M | $400.9M | $578.2M | $350.2M | $593.1M |
Related companies: ABCL · CLDX · EWTX · GLPG · GPCR · MESO · NUVB
More sections of QURE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks